Jaime-Jürgen Eulert-Grehn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jaime-Jürgen Eulert-Grehn has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Christoph Starck
German Heart Ctr Berlin, Dept Cardiothorac & Vasc Surg, Augustenburger Pl 1, D-13353 Berlin, Germany
4 shared publicationsEvgenij Potapov
German Heart Ctr Berlin, Dept Cardiothorac & Vasc Surg, Augustenburger Pl 1, D-13353 Berlin, Germany
4 shared publicationsVolkmar Falk
Department of Cardiothoracic and Vascular Surgery, German Heart Center Berlin, Berlin, Germany
4 shared publications- Volkmar Falk
Deutsches Herzzentrum der Charité, Charité University Medicine Berlin , Berlin
4 shared publications - Christoph Starck
Deutsches Herzzentrum der Charité (DHZC), Department of Cardiothoracic and Vascular Surgery, Augustenburger Platz 1, 13353 Berlin, Germany
3 shared publications A. Stepanenko
Deutsches Herzzentrum Berlin
2 shared publications
Latest Publications
- 26 February 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (6) , 810-817
Defibrillator generator replacements in patients with left ventricular assist device support: The risks of hematoma and infection
- 26 February 2022
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 41 (6) , 810-817
Defibrillator generator replacements in patients with left ventricular assist device support: The risks of hematoma and infection
- 15 February 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (11) , 1332-1338
Interventional Procedures for Left Ventricular Assist Device-Associated Complications
As patients on long-term left ventricular assist device (LVAD) face a substantial risk for open cardiac reoperation, interventional treatment approaches are becoming increasingly important in this population. We evaluated data of 871 patients who were on LVAD support between January 1, 2016 and December 1, 2020. Interventional treatments for LVAD-associated complications were performed in 76 patients. Seventeen patients underwent transcatheter aortic valve replacements (TAVR) and 61 patients underwent outflow graft interventions (OGI). TAVR improved symptoms in patients with severe symptomatic aortic regurgitation. Postinterventional complications included aggravation of preexisting right heart failure (RHF), third-degree atrioventricular block, and intrapump thrombosis (in 3 [16.7%], 2 [11.1%], and 1 [5.6%] patients, respectively). In outflow graft obstructions, OGI led to recovery of LVAD flow (p < 0.001), unloading of the left ventricle (p = 0.004), decrease of aortic valve opening time (p = 0.010), and improvement of right heart function (p < 0.001). Complications included bleeding, RHF, and others (in 9 [10.8%], 5 [6.0%], and 5 [6.0%] patients, respectively). Eight (9.6%) patients died within the hospital stay after OGI, including mortality secondary to prolonged cardiogenic shock. In conclusion, interventional procedures are a feasible and safe treatment modality for LVAD-associated complications.
- 15 February 2022
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 68 (11) , 1332-1338
Interventional Procedures for Left Ventricular Assist Device-Associated Complications
As patients on long-term left ventricular assist device (LVAD) face a substantial risk for open cardiac reoperation, interventional treatment approaches are becoming increasingly important in this population. We evaluated data of 871 patients who were on LVAD support between January 1, 2016 and December 1, 2020. Interventional treatments for LVAD-associated complications were performed in 76 patients. Seventeen patients underwent transcatheter aortic valve replacements (TAVR) and 61 patients underwent outflow graft interventions (OGI). TAVR improved symptoms in patients with severe symptomatic aortic regurgitation. Postinterventional complications included aggravation of preexisting right heart failure (RHF), third-degree atrioventricular block, and intrapump thrombosis (in 3 [16.7%], 2 [11.1%], and 1 [5.6%] patients, respectively). In outflow graft obstructions, OGI led to recovery of LVAD flow (p < 0.001), unloading of the left ventricle (p = 0.004), decrease of aortic valve opening time (p = 0.010), and improvement of right heart function (p < 0.001). Complications included bleeding, RHF, and others (in 9 [10.8%], 5 [6.0%], and 5 [6.0%] patients, respectively). Eight (9.6%) patients died within the hospital stay after OGI, including mortality secondary to prolonged cardiogenic shock. In conclusion, interventional procedures are a feasible and safe treatment modality for LVAD-associated complications.
- 1 January 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 70 (S 01) , S1-S61
Transcatheter Aortic Valve Implantation for Severe Aortic Regurgitation in Patients with Left Ventricular Assist Device Support
Background: Approximately 15% of patients on left ventricular assist device (LVAD) support develop severe aortic regurgitation (AR). Since patients on LVAD support are considered at high risk for reoperation, the interventional approach is becoming increasingly important in this patient cohort. Method: We conducted a retrospective analysis to evaluate the outcomes of patients on LVAD support, who underwent transcatheter aortic valve implantation (TAVI) at our institution between January 1, 2016, and December 1, 2020. Results: During the investigational period, 18 TAVI were performed in LVAD patients at our institution. Mean age was 62.4 (±9.6) years and 72.2% were male. Before LVAD implantation, no or mild AR was pre-existing. The time from LVAD implantation to severe AR ranged from 0.5 to 9.5 years. Seventeen (94.4%) interventions were performed via femoral access. In total 18 (78.3%) balloon-expandable valves and 5 (21.7%) self-expandable valves were implanted. Six (35.3%) patients showed trans-stent leak after valve implantation and were treated with valve-in-valve implantation. In five patients the implantation was performed during the same procedure, in one patient 69 days after index procedure. Overall, technical success according to the Valve Academic Research Consortium 3 (VARC-3) was achieved in 72.2% cases. 33.3% of patients were directly transferred from the recovery room to the normal ward; 50.0% of patients spent 1 or 2 days in the intensive care unit. The median length of hospital stay was 7.5 (4.5–20.75) days. Pre intervention, all patients presented with symptoms of HF of functional New York Heart Association class 3 or 4. After TAVI 77.8% of patients had no or only mild symptoms. In two patients minor vascular and access-related complications (as determined by VARC-3) occurred: one patient required endovascular stenting of the common femoral artery and the other conservative treatment of an arteriovenous fistula. Two patients suffered from third-degree atrioventricular block. One patient developed LVAD intra-pump thrombosis. No patient suffered from VARC type ≥ 2 bleeding. Post-TAVI right heart failure with need for inotropic support was seen in three patients, of which one died within the hospital stay. Another patient died due to sepsis of unknown origin in an external hospital. This resulted in an all-cause mortality of 10.2% at 30 days. Conclusion: TAVI is a safe and feasible way to treat severe aortic regurgitation in patients on LVAD support. Publication Date: 03 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- 1 January 2022
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 70 (S 01) , S1-S61
Transcatheter Aortic Valve Implantation for Severe Aortic Regurgitation in Patients with Left Ventricular Assist Device Support
Background: Approximately 15% of patients on left ventricular assist device (LVAD) support develop severe aortic regurgitation (AR). Since patients on LVAD support are considered at high risk for reoperation, the interventional approach is becoming increasingly important in this patient cohort. Method: We conducted a retrospective analysis to evaluate the outcomes of patients on LVAD support, who underwent transcatheter aortic valve implantation (TAVI) at our institution between January 1, 2016, and December 1, 2020. Results: During the investigational period, 18 TAVI were performed in LVAD patients at our institution. Mean age was 62.4 (±9.6) years and 72.2% were male. Before LVAD implantation, no or mild AR was pre-existing. The time from LVAD implantation to severe AR ranged from 0.5 to 9.5 years. Seventeen (94.4%) interventions were performed via femoral access. In total 18 (78.3%) balloon-expandable valves and 5 (21.7%) self-expandable valves were implanted. Six (35.3%) patients showed trans-stent leak after valve implantation and were treated with valve-in-valve implantation. In five patients the implantation was performed during the same procedure, in one patient 69 days after index procedure. Overall, technical success according to the Valve Academic Research Consortium 3 (VARC-3) was achieved in 72.2% cases. 33.3% of patients were directly transferred from the recovery room to the normal ward; 50.0% of patients spent 1 or 2 days in the intensive care unit. The median length of hospital stay was 7.5 (4.5–20.75) days. Pre intervention, all patients presented with symptoms of HF of functional New York Heart Association class 3 or 4. After TAVI 77.8% of patients had no or only mild symptoms. In two patients minor vascular and access-related complications (as determined by VARC-3) occurred: one patient required endovascular stenting of the common femoral artery and the other conservative treatment of an arteriovenous fistula. Two patients suffered from third-degree atrioventricular block. One patient developed LVAD intra-pump thrombosis. No patient suffered from VARC type ≥ 2 bleeding. Post-TAVI right heart failure with need for inotropic support was seen in three patients, of which one died within the hospital stay. Another patient died due to sepsis of unknown origin in an external hospital. This resulted in an all-cause mortality of 10.2% at 30 days. Conclusion: TAVI is a safe and feasible way to treat severe aortic regurgitation in patients on LVAD support. Publication Date: 03 February 2022 (online) © 2022. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
- Open Access
- 1 May 2021
- Published by AME Publishing Company in Annals of Cardiothoracic Surgery
- Vol. 10 (3) , 408-410
Continuous-flow biventricular mechanical support implantation strategies
Continuous-flow biventricular mechanical support implantation strategies
- 1 May 2021
- Published by AME Publishing Company in Annals of Cardiothoracic Surgery
- Vol. 10 (3) , 408-410
Open AccessContinuous-flow biventricular mechanical support implantation strategies
Continuous-flow biventricular mechanical support implantation strategies
- 4 February 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 60 (2) , 431
Hemoptysis due to a primary aortobronchial fistula of the ascending aorta
European Journal of Cardio-Thoracic Surgery thanks Luca Di Marco, Stoyan Kostadinov Kondov and the other, anonymous reviewer(s) for their contribution to the peer review process of this article.
- 4 February 2021
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 60 (2) , 431
Hemoptysis due to a primary aortobronchial fistula of the ascending aorta
European Journal of Cardio-Thoracic Surgery thanks Luca Di Marco, Stoyan Kostadinov Kondov and the other, anonymous reviewer(s) for their contribution to the peer review process of this article.
- 1 February 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 111 (2) , e135-e137
ECMELLA 2.0: Single Arterial Access Technique for a Staged Approach in Cardiogenic Shock
- 1 February 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 111 (2) , e135-e137
ECMELLA 2.0: Single Arterial Access Technique for a Staged Approach in Cardiogenic Shock
- 21 July 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (10) , 1078-1085
Safety of bioelectrical impedance analysis in advanced heart failure patients
Background: Cardiac cachexia and frailty are major complications of advanced heart failure (AHF). Bioelectrical impedance analysis (BIA) may provide valuable information regarding fluid balance, muscle mass and prognosis. The main concerns regarding the use of BIA in AHF patients remain arrhythmias and electromagnetic interferences with cardiac implantable electronic devices (CIEDs). Reliable data regarding patients on continuous‐flow ventricular assist device (cf‐VAD) remain scarce. The aim of this study is to evaluate the safety of BIA in AHF patients on pro‐arrhythmogenic therapy with an implanted CIED and/or with a cf‐VAD.Methods: We prospectively performed 217 BIA measurements in 143 AHF patients at risk of severe arrhythmias due to inotropic support/a history of ventricular arrhythmias and/or treated with CIED, including 104 patients with an ICD, CRT or pacemaker and 95 patients with a cf‐VAD. All patients were under continuous Electrocardiogram (ECG) monitoring and clinical surveillance for 24 hours.Results: No adverse events were observed during the 217 BIA measurements: No rhythm disturbances were documented in the telemetric monitoring during or within 30 minutes after the measurement. CIEDs showed no malfunction, regardless of the location measured or the device manufacturer. In particular, no inappropriate shocks were observed. No alarms, flow disturbances, or malfunctions of the cf‐VAD occurred during or after the measurements.Conclusion: We consider BIA a safe measurement with major clinical relevance in our cohort of AHF patients, despite an increased arrhythmic potential on inotropic support or the presence of implanted electronic devices (ICD, CRT, pacemaker and cf‐VAD).
- 21 July 2020
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 43 (10) , 1078-1085
Safety of bioelectrical impedance analysis in advanced heart failure patients
Background: Cardiac cachexia and frailty are major complications of advanced heart failure (AHF). Bioelectrical impedance analysis (BIA) may provide valuable information regarding fluid balance, muscle mass and prognosis. The main concerns regarding the use of BIA in AHF patients remain arrhythmias and electromagnetic interferences with cardiac implantable electronic devices (CIEDs). Reliable data regarding patients on continuous‐flow ventricular assist device (cf‐VAD) remain scarce. The aim of this study is to evaluate the safety of BIA in AHF patients on pro‐arrhythmogenic therapy with an implanted CIED and/or with a cf‐VAD.Methods: We prospectively performed 217 BIA measurements in 143 AHF patients at risk of severe arrhythmias due to inotropic support/a history of ventricular arrhythmias and/or treated with CIED, including 104 patients with an ICD, CRT or pacemaker and 95 patients with a cf‐VAD. All patients were under continuous Electrocardiogram (ECG) monitoring and clinical surveillance for 24 hours.Results: No adverse events were observed during the 217 BIA measurements: No rhythm disturbances were documented in the telemetric monitoring during or within 30 minutes after the measurement. CIEDs showed no malfunction, regardless of the location measured or the device manufacturer. In particular, no inappropriate shocks were observed. No alarms, flow disturbances, or malfunctions of the cf‐VAD occurred during or after the measurements.Conclusion: We consider BIA a safe measurement with major clinical relevance in our cohort of AHF patients, despite an increased arrhythmic potential on inotropic support or the presence of implanted electronic devices (ICD, CRT, pacemaker and cf‐VAD).
- Open Access
- 22 October 2019
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 22 (1) , 133-138
Transcatheter aspiration of large pacemaker and implantable cardioverter-defibrillator lead vegetations facilitating safe transvenous lead extraction
Aims: Treatment of patients with systemic cardiac implantable electronic device (CIED) infection with large lead vegetations is challenging and associated with relevant morbidity and mortality. To avoid complications from open surgical extraction, a novel approach with percutaneous aspiration of large vegetations prior to transvenous lead extraction was instituted. The results of this treatment concept were retrospectively analysed in this multicentre study. Methods and results: One hundred and one patients [mean age 68.2 ± 13.1 (30–92) years] were treated in four centres for endovascular CIED infection with large lead vegetations. Mean lead vegetation size was 30.7 ± 13.5 mm. Two hundred and forty-seven leads were targeted for extraction (170 pacemaker leads, 77 implantable cardioverter-defibrillator leads). Mean lead implant duration was 81.7 (1–254) months. The transcatheter aspiration system with a specialized long venous drainage cannula and a funnel-shaped tip was based on a veno-venous extracorporeal circuit with an in-line filter. The aspiration of vegetations showed complete procedural success in 94.0% (n = 95), partial success in 5.0% (n = 5). Three major complications (3.0%) were encountered. Complete procedural success (per lead) of the subsequently performed transvenous lead extraction procedure was 99.2% (n = 245). Thirty-day mortality was 3.0% (n = 3). Five patients (5.0%) died in the further course on Days 51, 54, 68, 134, and 182 post-procedure (septic complications: n = 4; heart failure: n = 1). Conclusion: The percutaneous aspiration procedure is highly effective and is associated with a low complication profile. The aspiration of vegetations immediately prior and during the lead extraction procedure may avoid septic embolization into the pulmonary circulation. This may potentially lead to a long-term survival benefit.
- 22 October 2019
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 22 (1) , 133-138
Open AccessTranscatheter aspiration of large pacemaker and implantable cardioverter-defibrillator lead vegetations facilitating safe transvenous lead extraction
Aims: Treatment of patients with systemic cardiac implantable electronic device (CIED) infection with large lead vegetations is challenging and associated with relevant morbidity and mortality. To avoid complications from open surgical extraction, a novel approach with percutaneous aspiration of large vegetations prior to transvenous lead extraction was instituted. The results of this treatment concept were retrospectively analysed in this multicentre study. Methods and results: One hundred and one patients [mean age 68.2 ± 13.1 (30–92) years] were treated in four centres for endovascular CIED infection with large lead vegetations. Mean lead vegetation size was 30.7 ± 13.5 mm. Two hundred and forty-seven leads were targeted for extraction (170 pacemaker leads, 77 implantable cardioverter-defibrillator leads). Mean lead implant duration was 81.7 (1–254) months. The transcatheter aspiration system with a specialized long venous drainage cannula and a funnel-shaped tip was based on a veno-venous extracorporeal circuit with an in-line filter. The aspiration of vegetations showed complete procedural success in 94.0% (n = 95), partial success in 5.0% (n = 5). Three major complications (3.0%) were encountered. Complete procedural success (per lead) of the subsequently performed transvenous lead extraction procedure was 99.2% (n = 245). Thirty-day mortality was 3.0% (n = 3). Five patients (5.0%) died in the further course on Days 51, 54, 68, 134, and 182 post-procedure (septic complications: n = 4; heart failure: n = 1). Conclusion: The percutaneous aspiration procedure is highly effective and is associated with a low complication profile. The aspiration of vegetations immediately prior and during the lead extraction procedure may avoid septic embolization into the pulmonary circulation. This may potentially lead to a long-term survival benefit.
- 5 May 2019
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 29 (3) , 484-486
Externalized conductor of a Kentrox lead and an unexpected insulation failure
Cardiac resynchronization therapy-defibrillator device upgrades may represent a challenging scenario, especially because unexpected findings can increase procedure difficulty. One such unexpected finding represents insulation failure with unremarkable device interrogation. Insulation failure due to an externalized conductor of an implantable cardiac defibrillator-lead has been recently described for the Kentrox lead (Biotronik). Another challenging aspect of device upgrades is the presence of venous thrombosis as in this case. Here, we report an inside-out abrasion of a Kentrox lead, an unexpected second insulation failure found during pocket revision and the successful recanalization in a patient with known left subclavian vein thrombosis.
- 5 May 2019
- Published by Oxford University Press (OUP) in Interactive CardioVascular and Thoracic Surgery
- Vol. 29 (3) , 484-486
Externalized conductor of a Kentrox lead and an unexpected insulation failure
Cardiac resynchronization therapy-defibrillator device upgrades may represent a challenging scenario, especially because unexpected findings can increase procedure difficulty. One such unexpected finding represents insulation failure with unremarkable device interrogation. Insulation failure due to an externalized conductor of an implantable cardiac defibrillator-lead has been recently described for the Kentrox lead (Biotronik). Another challenging aspect of device upgrades is the presence of venous thrombosis as in this case. Here, we report an inside-out abrasion of a Kentrox lead, an unexpected second insulation failure found during pocket revision and the successful recanalization in a patient with known left subclavian vein thrombosis.
- 12 June 2018
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 41 (9) , 1266-1267
Inadvertent pacemaker lead dislodgement
Transcatheter aortic valve implantation (TAVI) has become an established treatment option for aortic valve stenosis in patients with a high risk for conventional surgical valve replacement. A well‐known complication is the development of conduction abnormalities. In the case of a new third‐degree atrioventricular block, the complication can be life‐threatening and permanent pacing is needed. Often these patients have a venous sheath placed in the jugular vein for the perioperative period. We report a case of inadvertent dislodgement of a permanent pacemaker lead after removal of a preoperatively placed venous sheath in a TAVI patient.
- 12 June 2018
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 41 (9) , 1266-1267
Inadvertent pacemaker lead dislodgement
Transcatheter aortic valve implantation (TAVI) has become an established treatment option for aortic valve stenosis in patients with a high risk for conventional surgical valve replacement. A well‐known complication is the development of conduction abnormalities. In the case of a new third‐degree atrioventricular block, the complication can be life‐threatening and permanent pacing is needed. Often these patients have a venous sheath placed in the jugular vein for the perioperative period. We report a case of inadvertent dislodgement of a permanent pacemaker lead after removal of a preoperatively placed venous sheath in a TAVI patient.